Q3 2021

Filed Oct 28, 2021 · 10-Q · 28 days after period end · 0001091818-21-000138

Q3 2021 · 10-Q

Revenue—

Net Income

-$113.86K

N/M vs Q3 2020

EPS Diluted

$0.00

N/M vs Q3 2020

Operating Cash Flowderived-$8,677N/M

Same quarter

Metric	Q3 2021	Q3 2020	Q3 2019	Q3 2018
Revenue	—	—	$5.96K	$5.51K
Net Income	-$113.86K	-$117.92K	-$6.33K	-$6.64K
EPS Diluted	$0.00	-$0.01	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR